BR112019012688A2 - método para produção de derivado de 7h-pirrol[2,3-d]pirimidina e intermediário sintético do mesmo - Google Patents

método para produção de derivado de 7h-pirrol[2,3-d]pirimidina e intermediário sintético do mesmo Download PDF

Info

Publication number
BR112019012688A2
BR112019012688A2 BR112019012688-0A BR112019012688A BR112019012688A2 BR 112019012688 A2 BR112019012688 A2 BR 112019012688A2 BR 112019012688 A BR112019012688 A BR 112019012688A BR 112019012688 A2 BR112019012688 A2 BR 112019012688A2
Authority
BR
Brazil
Prior art keywords
compound
formula
salt
quím
petition
Prior art date
Application number
BR112019012688-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Higashi Akinobu
Klarskov Petersen Anders
Takiguchi Hiromu
Bornholdt Jan
Lebek Jensen Kim
Vedsoe Per
Ebdrup Soren
Inaba Takashi
Watanabe Takashi
Takeichi Tsubasa
Original Assignee
Japan Tobacco Inc
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc, Leo Pharma As filed Critical Japan Tobacco Inc
Publication of BR112019012688A2 publication Critical patent/BR112019012688A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32Oxygen atoms
    • C07D307/33Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BR112019012688-0A 2016-12-21 2017-12-20 método para produção de derivado de 7h-pirrol[2,3-d]pirimidina e intermediário sintético do mesmo BR112019012688A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016247607 2016-12-21
PCT/JP2017/045729 WO2018117152A1 (ja) 2016-12-21 2017-12-20 7H-ピロロ[2,3-d]ピリミジン誘導体の製造方法及びその合成中間体

Publications (1)

Publication Number Publication Date
BR112019012688A2 true BR112019012688A2 (pt) 2019-11-19

Family

ID=62627423

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019012688-0A BR112019012688A2 (pt) 2016-12-21 2017-12-20 método para produção de derivado de 7h-pirrol[2,3-d]pirimidina e intermediário sintético do mesmo

Country Status (12)

Country Link
US (3) US11673900B2 (enExample)
EP (1) EP3560932A4 (enExample)
JP (2) JP6434678B2 (enExample)
KR (1) KR102546513B1 (enExample)
CN (2) CN117865992A (enExample)
AU (2) AU2017384317C1 (enExample)
BR (1) BR112019012688A2 (enExample)
CA (1) CA3047891A1 (enExample)
IL (2) IL288080B2 (enExample)
MX (2) MX2019007542A (enExample)
TW (2) TWI816651B (enExample)
WO (1) WO2018117152A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180025940A (ko) 2015-07-07 2018-03-09 니뽄 다바코 산교 가부시키가이샤 7H-피롤로[2,3-d]피리미딘 유도체의 제조 방법 및 그의 중간체
CN117865992A (zh) 2016-12-21 2024-04-12 日本烟草产业株式会社 7H-吡咯并[2,3-d]嘧啶衍生物的制备方法及其合成中间体
CN111560021B (zh) * 2020-06-30 2023-05-26 上海鲲博玖瑞医药科技发展有限公司 一种德高替尼中间体及其制备方法
CN111606929B (zh) * 2020-06-30 2023-07-07 中瀚(齐河县)生物医药科技有限公司 德高替尼的制备方法
CN111574540B (zh) * 2020-06-30 2023-08-29 云南华派医药科技有限公司 一种德高替尼的制备方法
CN121175050A (zh) 2023-03-17 2025-12-19 利奥药品公司 用于治疗患有中度至重度慢性手部湿疹的患者的慢性手部湿疹的方法
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ras抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662960B2 (en) 2001-04-26 2010-02-16 Choongwae Pharma Corporation Beta-strand mimetics and method relating thereto
NZ543790A (en) * 2003-05-30 2009-09-25 Choongwae Pharma Corp Beta-strand mimetics and methods relating thereto
US7230119B2 (en) 2004-08-25 2007-06-12 Biocryst Pharmaceuticals, Inc. Process for the preparation of substituted pyrrolidine derivatives and intermediates
EP2078022B1 (en) 2006-09-22 2011-11-09 Janssen Pharmaceutica N.V. Spiro benzazepines used as vasopressin antagonists
TWI466885B (zh) 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
BR112013018286A2 (pt) 2011-01-19 2016-11-16 Galapagos Nv derivados d azetidina úteis para o tratamento de doenças metabólicas e inflamatórias
CN103570601B (zh) 2012-07-20 2016-03-30 重庆博腾制药科技股份有限公司 一种光学活性药物中间体的制备方法
WO2014138053A1 (en) * 2013-03-05 2014-09-12 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
JP6500634B2 (ja) * 2015-06-24 2019-04-17 株式会社Ihi 溶接装置及び溶接方法
KR20180025940A (ko) * 2015-07-07 2018-03-09 니뽄 다바코 산교 가부시키가이샤 7H-피롤로[2,3-d]피리미딘 유도체의 제조 방법 및 그의 중간체
KR102788829B1 (ko) * 2016-12-21 2025-03-31 니뽄 다바코 산교 가부시키가이샤 야누스 키나제 억제제의 결정질 형태
CN117865992A (zh) * 2016-12-21 2024-04-12 日本烟草产业株式会社 7H-吡咯并[2,3-d]嘧啶衍生物的制备方法及其合成中间体

Also Published As

Publication number Publication date
TWI854815B (zh) 2024-09-01
IL267385B1 (enExample) 2023-02-01
MX2024005335A (es) 2024-05-20
JP7098496B2 (ja) 2022-07-11
US11673900B2 (en) 2023-06-13
AU2017384317B2 (en) 2022-03-10
KR102546513B1 (ko) 2023-06-23
CN110300756A (zh) 2019-10-01
WO2018117152A1 (ja) 2018-06-28
KR20190095408A (ko) 2019-08-14
RU2019122691A3 (enExample) 2021-02-08
TW201829422A (zh) 2018-08-16
TWI816651B (zh) 2023-10-01
IL288080B2 (en) 2024-03-01
EP3560932A1 (en) 2019-10-30
JP2019048806A (ja) 2019-03-28
AU2017384317C1 (en) 2022-06-30
JPWO2018117152A1 (ja) 2018-12-20
JP6434678B2 (ja) 2018-12-05
IL267385A (enExample) 2019-07-31
EP3560932A4 (en) 2020-10-28
MX2019007542A (es) 2019-11-18
US20240140967A1 (en) 2024-05-02
CN110300756B (zh) 2024-01-02
RU2019122691A (ru) 2021-01-25
CN117865992A (zh) 2024-04-12
US12195481B2 (en) 2025-01-14
US20200216470A1 (en) 2020-07-09
CA3047891A1 (en) 2018-06-28
AU2022203506A1 (en) 2022-06-09
US20250084106A1 (en) 2025-03-13
IL288080B1 (en) 2023-11-01
AU2022203506B2 (en) 2024-02-08
IL288080A (en) 2022-01-01
AU2017384317A1 (en) 2019-07-11
IL267385B2 (en) 2023-06-01
TW202400613A (zh) 2024-01-01

Similar Documents

Publication Publication Date Title
BR112019012688A2 (pt) método para produção de derivado de 7h-pirrol[2,3-d]pirimidina e intermediário sintético do mesmo
EP3321271B1 (en) Method for producing 7h-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof
ES2728353T3 (es) Compuesto de (6S,9aS)-N-bencil-6-[(4-hidroxifenil)metil]-4,7-dioxo-8-({6-[3-(piperazin-1-il)azetidin-1-il]piridin-2-il}metil)-2-(prop-2-en-1-il)-octahidro-1H-pirazino[2,1-c][1,2,4]triazin-1-carboxamida
BR112019012267A2 (pt) processo para a preparação do derivado de 7h-pirrolo [2,3-d]pirimidina e cocristais do mesmo
AU2017380213A1 (en) Crystalline forms of a janus kinase inhibitor
RU2776802C2 (ru) Способ получения производных 7h-пирроло[2,3-d]пиримидина и промежуточных продуктов для их синтеза
JP6970295B2 (ja) イソキノリニルスルホニル誘導体およびその使用

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 519/00 , C07C 271/22 , C07D 307/33 , C07D 403/06 , C07D 487/10 , C07D 491/10

Ipc: C07D 519/00 (2006.01), C07C 271/22 (2006.01), C07D

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25G Requested change of headquarter approved

Owner name: LEO PHARMA A/S (DK) ; JAPAN TOBACCO, INC. (JP)

B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]